Cytox Expands Collaboration with AIBL to Identify Those Most at Risk to Rapidly Progress to Alzheimer’s
Cytox, a precision medicine company which today is commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s disease (AD) and other neurological diseases, has announced it has expanded its research collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) to test new algorithms for identifying the pre-symptomatic and mild cognitively impaired people most at risk to progress to AD.
Under the expanded agreement Cytox will assess genetic risk for accelerated development of AD using its current, commercially available, research use only approaches developed to run on the Thermo Fisher Scientific Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform. AIBL will provide biobank samples together with associated longitudinal data from study research participants clinically diagnosed as cognitively normal, with mild cognitive impairment or with AD. Each subject has confirmed amyloid status from PET imaging, with some of the subjects remaining cognitively stable and others cognitively declining during the study period.
Genotyping of DNA samples will be performed by Cytox’s validated Australian genotyping services partner, Ramaciotti Centre for Genomics, a national infrastructure facility delivering internationally competitive genomic services and based in Sydney, Australia.
“The AIBL biobank presents a tremendous research opportunity due to the number of blood samples from subjects which are extremely well characterized both in terms of cognitive performance and biomarker status over a significant period of time,” states Dr. Richard Pither, CEO of Cytox. “By working closely with AIBL and its researchers, led by AIBL genetic lead, Dr. Simon Laws, we will explore the performance of our PRS approaches for assessing genetic risk for progressing from initial symptoms to fully symptomatic AD.
“Through this collaborative work we foresee the data generated will help drug developers running clinical trials and sponsors of large cohort studies better stratify their subjects based on accelerated disease development risk. Over time, and as new treatments for AD make it to market, we plan to make the products and services that result from this collaboration available for routine clinical practice.”
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Odaseva Appoints New Chief Legal Officer19.6.2019 12:00:00 CEST | Pressemelding
Odaseva, the unified cloud data protection, compliance and operations platform for enterprises running Salesforce as a business-critical application, today announced the appointment of Richard Zolezzi as the company’s new chief legal officer. In his role, Zolezzi will oversee the company’s worldwide legal affairs and support finance and human resources operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005095/en/ Richard Zolezzi named Odaseva's new chief legal officer (Photo: Business Wire) “Richard’s unique experience in supporting enterprise software companies through strategic expansion makes him the perfect fit to join Odaseva during this exciting time of growth,” said Sovan Bin, CEO and founder of Odaseva. “The need for overall data protection and compliance solutions has driven an increased demand for our solution, and we are thrilled to leverage Richard’s expertise.” Most recently, Richard led the Northe
New Survey Finds Fragmented Processes and System Silos Slowing Clinical Trials19.6.2019 11:19:00 CEST | Pressemelding
There is an industrywide drive to streamline trial processes and systems for better study visibility and collaboration, according to the Veeva 2019 Unified Clinical Operations Survey, one of the largest-ever surveys of clinical operations professionals. New research from Veeva Systems (NYSE:VEEV) finds that all (100%) respondents surveyed report the need to improve information exchange among study partners. On average, they utilize at least three methods to share trial data and documents among sponsors, CROs, and sites, with email as the primary tool. Majorities say the move to streamline information exchange is driven by the need to reduce manual processes (71%), improve collaboration (66%), and increase visibility and oversight (64%) during trials. Nearly all sponsors and CROs (99%) say they also need to unify clinical applications for greater visibility (70%) and easier collaboration (61%). Many of the challenges in managing trials stem from siloed processes and systems that prevent
Geri Horner Test Drives RockStar Suites aboard Virgin Voyages’ Scarlet Lady19.6.2019 11:00:00 CEST | Pressemelding
Virgin Voyages is upping the game for its top suites aboard the highly anticipated Scarlet Lady, with new offerings to ensure that Mega RockStars won’t have to worry about a thing during their voyage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005107/en/ Geri Horner of the Spice Girls testing out Virgin Voyages Mega Rockstar Suites in New Video (Photo: Business Wire) Geri Horner Test Drives RockStar Suites In celebration of the expanded offerings, the brand has today released exclusive video content of the suites, which features Virgin Group founder, Sir Richard Branson, and legendary British pop star, Geri Horner, of the hugely successful girl group, the Spice Girls. The video documents Horner test driving the Virgin Voyages ‘Gorgeous Suite,’ one of the ship’s most glamorous cabins, as a favor to her longtime friend, Branson. Following Horner’s journey through the suite, the footage chronicles her full RockStar ex
beqom Study Shows U.S., UK Employees Aware of Gender Wage Gaps but Not of Actions Taken by Employers or Governments to Close Them19.6.2019 11:00:00 CEST | Pressemelding
Despite three in four workers (75%) saying they are aware of gender pay gaps existing in their country, nearly one in five (19%) admit they are not aware. More U.S. workers (21%) are unaware of gender pay gaps than UK workers (17%); among age groups, Millennials (24%) are the most unaware, compared to 16% of Gen Zs and 11% of Baby Boomers. These findings are according to beqom’s The Gender Pay Gap: What Your Employees Really Think report, which assesses enterprise worker perception on progress made in the last year to improve the gender pay gap in the U.S. and UK and aims to uncover employee perceptions about pay and identify areas for improvement. When it comes to preventing or closing pay gaps, employees believe the U.S. significantly trails the UK, with nearly one-third of UK workers (32%) saying their employer has announced a commitment to solve the pay gap compared to 13% of U.S. workers. Additionally, more UK workers (18%) say their employer has adjusted salaries for female emplo
Moon-Walking Mini-Breaks, 3D-Printed Room Service and Hyper-Personalised Spaces: Welcome to the Hotel of 211919.6.2019 10:05:00 CEST | Pressemelding
Intergalactic getaways, fast-food nutrient pills, 2-3 hour working days and adaptable, personalised rooms that can transport guests everywhere from jungles to mountain ranges; in celebration of its 100th anniversary, today Hilton (NYSE: HLT) predicts the future trends set to dominate the travel and hospitality industry in the next 100 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005341/en/ Autonomous shooting travel pods will drop guests off at mesmerising destinations, while miniature eco-systems protected from the elements by bubble-like structures will mirror their surroundings (Photo: Business Wire) In a report supported by expert insight from the fields of sustainability, innovation, design, human relations and nutrition, findings reveal how the growing sophistication of technology and climate change will impact the hotel industry in the future. Key predictions for the hotel of the future include: Persona
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA19.6.2019 10:00:00 CEST | Pressemelding
Invivoscribe is pleased to announce that on June 5th the Ministry of Health, Labor and Welfare (MHLW) approved our LeukoStrat® CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo’s Quizartinib for the treatment of FLT3-ITD positive relapse/ refractory acute myeloid leukemia (AML) patients in Japan. At the same time the Japanese MHLW added approval in use of EDTA collection tubes to the existing approval of heparin collection tubes used with this assay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005222/en/ Invivoscribe Headquarters - San Diego, CA (Photo: Business Wire) The QuANTUM-R study demonstrated that quizartinib resulted in a statistically significant improvement in overall survival (OS) compared to salvage chemotherapy when patients were selected with the LeukoStrat CDx FLT3 Mutation Assay. Mutations in the FLT3 gene are among the most important driver mutations in AML. This milestone furt